SMC-LUD: Liver Ultrasound Dataset (HCC vs Hemangioma)

The dataset consists of 5,466 anonymized 2D B-mode ultrasound images categorized into two classes. The distribution of images for training and testing is detailed in [Table 1].
The full dataset, including class labels and metadata, is publicly available in a data repository under a CC-BY license. It is organized into two main directories according to class: hepatocellular carcinoma (HCC), hemangioma. Within each class directory, images are further grouped by patients, with each patient assigned a unique subdirectory containing all associated ultrasound images.

The dataset generated and analyzed during the current study is publicly available for non-commercial research use only, in consideration of patient privacy. This study was approved by the Data Review Board of Samsung Medical Center (SMC) (DRB No. 2025-0111).

Table 1. Dataset Classes
Diagnosis
Subgroup
No. of Patients
No. of Images
Train
Validation
Test
Hemangioma
Clean
323
1,267
886
253
128
Caliper
374
1,402

Subtotal
422
2,669

HCC
Clean
421
1,389
972
277
178
Caliper
557
1,327

Subtotal
600
2,716

Clean (Trained)
744
2,656
1,858
530
306
Total

1,021
5,385
3,769
1,076
540

A metadata file in CSV format is provided, containing the following columns: patient_id, image_filename, class_label, and additional clinical or acquisition metadata as available. Each row in the CSV file corresponds to a single image and provides the relevant annotation and metadata.
Table 2. Patient and Tumor Characteristics
Characteristic
HCC (patients=600)
Hemangioma (patients=421)
Demographics
Age, years
66.65 ± 11.02 (20–90)
55.50 ± 12.76 (30–90)
Sex, male
491 (81.8%)
174 (41.3%)
Sex, female
109 (18.2%)
247 (58.7%)
Height, cm
163.57 ± 16.39
163.72 ± 8.45
Weight, kg
67.44 ± 11.24 (42–104)
63.85 ± 12.95 (34–118)
Tumor characteristics
Max diameter, cm
2.90/2.10/4.50(Median/Q1/Q3)
–
UICC stage (2000)
pT1
58 (9.7%)
–
pT2
120 (20.0%)
–
pT3
353 (58.8%)
–
pT4
69 (11.5%)
–
AJCC stage (2010)
pT1
164 (27.3%)
–
pT2
393 (65.5%)
–
pT3
22 (3.7%)
–
pT4
21 (3.5%)
–